STOCK TITAN

Sunshine Biopharma Inc - SBFMW STOCK NEWS

Welcome to our dedicated news page for Sunshine Biopharma (Ticker: SBFMW), a resource for investors and traders seeking the latest updates and insights on Sunshine Biopharma.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Sunshine Biopharma's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Sunshine Biopharma's position in the market.

Rhea-AI Summary
Sunshine Biopharma, Inc. (NASDAQ: 'SBFM') has relocated its headquarters to New York City while maintaining a satellite office in Montreal, Canada. The company operates a Canadian subsidiary with 41 employees and 51 generic prescription drugs on the market, planning to expand to 67 by 2024. Sunshine Biopharma is also conducting a proprietary drug development program for liver cancer and COVID-19. The press release contains forward-looking statements and emphasizes the risks and uncertainties involved in the company's activities.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.59%
Tags
none
-
Rhea-AI Summary
Sunshine Biopharma Inc. reports Q2 gross revenues of $5,560,865, a 3,600% increase YoY. Acquiring Nora Pharma Inc. contributed to the growth. Q2 revenues also increased by 13.6% compared to Q1.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
earnings
-
Rhea-AI Summary
Sunshine Biopharma Inc. has closed its private placement, raising approximately $5 million in gross proceeds. The company issued 5,952,381 units and pre-funded units at a purchase price of $0.84 per unit. Each unit or pre-funded unit includes one share of common stock and two non-tradable warrants. The warrants have a term of five and a half years. Aegis Capital Corp. acted as the Exclusive Placement Agent for the offering.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.52%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-18.78%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
69.81%
Tags
earnings
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9%
Tags
earnings
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.11%
Tags
covid-19
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.11%
Tags
none
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.49%
Tags
buyback
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.14%
Tags
none
Sunshine Biopharma Inc

Nasdaq:SBFMW

SBFMW Rankings

SBFMW Stock Data

24.62M
Research and Development in Biotechnology
Professional, Scientific, and Technical Services
Link
United States
New York

About SBFMW

sunshine biopharma inc (sbfm) is a pharmaceuticals company based out of 469 jean-talon west, 3rd floor, montreal, québec, canada.